Biogen BIIB reported third-quarter 2026 adjusted earnings per share (EPS) of $2.62, which beat the Zacks Consensus Estimate ...

Biogen Canada Inc. acknowledges the draft recommendation from Canada's Drug Agency (CDA) that supports a significant ...

Spinraza (nusinersen) is a brand-name injection prescribed for spinal muscular atrophy in adults and children. As with other drugs, Spinraza can cause side effects, such as fever, headache, and ...

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended ...

Biogen reported new phase 3 data for its superpricey Spinraza on Monday. Hoping to win over careful payers, Biogen has new data to support its superpricey spinal muscular atrophy (SMA) drug Spinraza.

Spinraza (nusinersen) is a prescription drug used to treat spinal muscular atrophy in adults and children. Spinraza’s cost may depend on factors such as your treatment plan and whether you have health ...

Spinraza (nusinersen) is a brand-name drug prescribed for spinal muscular atrophy (SMA) in adults and children. It’s given via spinal injection by a healthcare professional. The dosage of Spinraza is ...

It’s been just over six months since Biogen’s pricey spinal muscular atrophy medication, Spinraza, won FDA approval, and as far as coverage goes, things are looking better for the drugmaker than some ...

Biogen Inc (NASDAQ:BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA. RESPOND is an ongoing two-year, phase 4 open-label ...

CARLSBAD, Calif., June 1, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the European Commission (EC) has granted marketing authorization for SPINRAZA ® ...

Spinraza (nusinersen) is a prescription drug used to treat spinal muscular atrophy. Spinraza can cause side effects that range from mild to serious. Examples include headache and fever. Keep reading ...